Predictive Oncology (NASDAQ: POAI) recently announced
the appointment of Pam Prior, CPA, to the company’s Board of Directors. In
addition to holding a seat on the board, Prior will also chair the company’s
audit committee. An article further discussing the company reads, “Prior, 57,
joins POAI’s Board of Directors with 35 years of experience in accounting,
mainly in management as CFO or controller. As the founder and CEO of Priorities
Group Inc., a provider of CFO services to small and mid-sized businesses, she
has served as a CFO to a number of companies, including Gentris Corp., a
private pharmacogenomics company subsequently purchased by Cancer Genetics Inc.
Most recently, Prior was CFO at Schiller Grounds Care, a privately held
lawn-and-garden equipment manufacturer. . . . Other previous CFO experience
includes working with companies in the health-industry space such as Global
Specimen Solutions, a privately held technology company for specimen and
consent management (later purchased by Covance), and multimillion-dollar
companies in other industries such as Greatwide Truckload Management, a $300
million subsidiary of a $1 billion, privately held, logistics company.”
To view the full article, visit http://ibn.fm/JPB3F
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (domestic, international, clinical, CRO and DCHIP), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics
applies artificial intelligence to its rich data gathered from patient tumors
to both personalize cancer therapies for patients and drive the development of
new targeted therapies in collaborations with pharmaceutical companies.
Helomics’ CLIA-certified lab provides clinical testing that assists oncologists
in individualizing patient-treatment decisions by providing an evidence-based
road map for therapy. In addition to its proprietary precision-oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (“D- CHIP”) to provide a tailored solution to its clients’
specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a
new rapid approach to growing tumors in the laboratory, which essentially
“fools” cancer cells into thinking they are still growing inside a patient. Its
proprietary Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific biomarkers. Once
the biomarkers are identified, they can be used in TumorGenesis’ Oncology
Capture Technology Platforms, which isolate and help categorize an individual
patient’s heterogeneous tumor samples to enable the development of
patient-specific treatment options. Helomics and TumorGenesis are focused on
ovarian cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA-cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and international
divisions. The company has achieved sales in five of the seven continents
through both direct sales and distributor partners. For more information, visit
the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
